Genentech Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GENENTECH, and what generic alternatives to GENENTECH drugs are available?
GENENTECH has nine approved drugs.
There are fifty-six US patents protecting GENENTECH drugs.
There are eight hundred and forty-four patent family members on GENENTECH drugs in fifty-three countries and eighty-six supplementary protection certificates in nineteen countries.
Summary for Genentech
| International Patents: | 844 |
| US Patents: | 56 |
| Tradenames: | 6 |
| Ingredients: | 6 |
| NDAs: | 9 |
| Patent Litigation for Genentech: | See patent lawsuits for Genentech |
| PTAB Cases with Genentech as patent owner: | See PTAB cases with Genentech as patent owner |
Drugs and US Patents for Genentech
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | ESBRIET | pirfenidone | CAPSULE;ORAL | 022535-001 | Oct 15, 2014 | AB | RX | Yes | Yes | 8,420,674 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
| Genentech Inc | ROZLYTREK | entrectinib | CAPSULE;ORAL | 212725-002 | Aug 15, 2019 | RX | Yes | Yes | 11,091,469 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-003 | Jan 11, 2017 | AB | RX | Yes | Yes | 8,084,475 | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-001 | Jan 11, 2017 | AB | RX | Yes | No | 7,566,729 | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Genentech
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-001 | Jan 11, 2017 | 9,561,217 | ⤷ Try a Trial |
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-003 | Jan 11, 2017 | 9,561,217 | ⤷ Try a Trial |
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-002 | Jan 11, 2017 | 9,561,217 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for GENENTECH drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 267 mg, 534 mg and 801 mg | ➤ Subscribe | 2018-10-15 |
International Patents for Genentech Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Portugal | 3428170 | ⤷ Try a Trial |
| Ukraine | 115861 | ⤷ Try a Trial |
| Peru | 20121502 | ⤷ Try a Trial |
| Japan | 2023071769 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Genentech Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1789390 | 170 12-2013 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: VISMODEGIB; REGISTRATION NO/DATE: EU/1/13/848/001 20130712 |
| 3143025 | PA2021010 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: RISDIPLAMAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA ; REGISTRATION NO/DATE: EU/1/21/1531 20210326 |
| 2176231 | LUC00191 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: ENTRECTINIB OU LES ISOMERES, TAUTOMERES, OU SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/20/1460 20200803 |
| 3143025 | C03143025/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: RISDIPLAM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67251 06.05.2021 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
